WJ35435
WJ35435 is a dual-targeted anticancer hybrid that induces anti-HDAC (in particular HDAC1 and HDAC6) and anti-topoisomerase I activities that causes DNA damage associated with a low DNA repair capability and induces cell cycle arrest at G1- and G2-phase to apoptosis. WJ35435 induces histone H3 acetylation and phosphorylation, α-tubulin acetylation and γ-H2AX formation to achieve anti-HDAC effect. WJ35435 is promising for research of cancer[1].
Product Specifications
CAS Number
[1620054-84-3]
UNSPSC
12352005
Target
Apoptosis; HDAC; Topoisomerase
Type
Reference compound
Related Pathways
Apoptosis; Cell Cycle/DNA Damage; Epigenetics
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/wj35435.html
Smiles
O=C(C1=CC=CC2=CC3=C(N=C21)C=CC=C3)NCCCCCC(NO)=O
Molecular Formula
C20H21N3O3
Molecular Weight
351.40
References & Citations
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
Recombinant Chromohalobacter salexigens NADH-quinone oxidoreductase subunit H (nuoH), partial
NTS (Neurotensin/Neuromedin N, Large Neuromedin N, NmN-125, Neuromedin N, NN, NmN, Neurotensin, NT, Tail Peptide) (MaxLight 750) discontinued
(2S)-7-Amino-2-((2S)-2-(6-amino-2-(4-carboxybutanamido)hexanamido)-6-(4-carboxybutanamido)hexanamido)heptanoic Acid
